MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS)

When you have open-heart surgery for conditions like blocked heart arteries (coronary artery disease) or a faulty heart valve (aortic valve stenosis), your heart needs to be stopped so the surgeons can operate. During this time, a special machine, often called a 'heart-lung machine' or 'conventional cardiopulmonary bypass' (cCPB), takes over the job of pumping blood and oxygen around your body. Although this machine is vital for surgery, it can sometimes lead to serious problems afterwards, like heart attack, stroke, kidney issues, or needing extra time in hospital.

Over the years, doctors have tried different ways to lower the risk of these complications. One newer approach is to use a smaller, 'miniaturised' heart-lung machine, known as 'minimally invasive extracorporeal circulation' (MiECC). The idea is that these smaller machines might be gentler on the body and cause fewer side effects than the traditional ones. However, because there are many different types of these smaller machines, and previous studies haven't been strong enough, we don't yet know for sure if they truly reduce risks for patients. As a result, most hospitals still use the standard heart-lung machine.

This important study, called MiECS, is designed to give us clear answers. It's one of the largest studies of its kind, involving many hospitals around the world. The main goal is to see if using the newer, smaller MiECC system during heart surgery leads to fewer serious problems like heart attack, stroke, or kidney damage within 30 days of the operation, compared to the standard machine. The study also hopes to find out if using the smaller machine means patients need fewer blood transfusions, can leave intensive care and the hospital sooner, and generally use fewer hospital resources during their recovery. The findings from this study could change how heart surgery is performed globally, helping to make it safer for many patients.